Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Stress-Response Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for eIF4G2/DAP5 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | eIF4G2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View eIF4G2 Products |
| Gene Delivery | eIF4G2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View eIF4G2 Products |
| Benchmark Ab | Anti-eIF4G2 Recombinant positive control for western blot and ELISA. |
View eIF4G2 Products |
| Validator | eIF4G2 siRNA Set For knockdown verification in cell-based assays. |
View eIF4G2 Products |
| Related Target A | eIF4E Synergistic translation initiation partner for cap-dependent cross-talk. |
View eIF4E Products |
| Related Target B | mTOR Upstream kinase regulator of the translation machinery. |
View mTOR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction Screening (PROTACs/Small Mol) | Recombinant eIF4G2 with strict structural integrity, Sequence Verified, High Purity (>95%). |
| Distinguishing Cap-dependent vs Independent translation | Orthogonal validation tools (siRNA) and homolog panels strictly verified by mass spec. |
| Lack of Reliable Assay Controls | Clinical-grade recombinant antibodies included as standardized benchmarks. |
| False Positives in Biochemical Assays | Endotoxin Controlled (<1EU/ug) proteins to ensure physiological cell assay conditions. |
Live eIF4G2/DAP5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for targeting translation initiation factors is intensifying as cancer resistance to traditional kinase inhibitors grows. eIF4G2 (DAP5), uniquely responsible for cap-independent, IRES-mediated translation during cellular stress and apoptosis, is emerging as a critical survival node in refractory tumors. As first-generation translation inhibitors face toxicity hurdles, the next wave of R&D is targeting highly specific eIF4G2-ribosome interactions via targeted protein degradation (PROTACs) and selective small molecules.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules | Academic / Early Biotech | Refractory Solid Tumors | Binding kinetics assay (Need high-purity recombinant eIF4G2 protein) |
| PROTACs | Preclinical Discovery Cos | Chemoresistant Cancers | Ternary complex validation (Need stable, sequence-verified domains) |
| RNAi / Antisense | Emerging Biopharma | Hematological Malignancies | Knockdown validation (Need precise benchmark Abs and siRNA controls) |